THR-149

Positive data announced for
Phase 2 Part A study in DME

Read the full press release

 

Tom Graney, CFA appointed CEO of Oxurion

 

Capital Commitment

Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

Read More

 

Review article

Potential of Pan-RGD integrin antagonists for treatment of retinal vascular disorders

Read more

 

THR-687

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

Read the full press release

 

Our mission

To prevent vision loss and address unmet medical needs in retinal disorders

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Advancing Science. Enhancing Vision.

Oxurion builds on years of experience resulting from local and international scientific collaboration. With our pipeline of innovative drug candidates for retinal disorders, we have a clear mission: to deliver solutions enabling vision preservation for people around the globe.  

We are advancing our pipeline of drug candidates to preserve vision for patients with retinal disorders and look forward to sharing the progress of our clinical programs.

- Patrik De Haes, MD, Non-Executive Chairman of Oxurion

 

3 reasons why we need to raise diabetic eye disease awareness

Read full story

Join forces to fight eye disease in developing countries

Read full story

9 striking facts about diabetic eye disease

Read full story

Careers

Oxurion employs 56 people worldwide, all are united by a shared goal: to make Oxurion a global leader in developing and commercializing innovative treatments for retinal disorders. Want to join us?

Visit our careers site

Partnerships

Oxurion relies on a network of experienced partners to bring the best possible eye care to patients across the globe. We are always open to new opportunities for partnership and collaboration for improving eye care.

Want to become a partner? Contact us!

Stay in touch

Be sure to check in regularly for the latest news about our our company, research & development activities and updates for investors or just subscribe to our mailing list to receive regular updates.

Read our latest news or Subscribe